JUBILANT DRAXIMAGE RADIOPHARMACIES, INC.

Jubilant DraxImage Radiopharmacies, Inc. specializes in the manufacturing and supply of radiopharmaceuticals for diagnostic and therapeutic applications in nuclear medicine. The company produces clinically critical isotopic agents, including Gallium-68 DOTATATE and other radiolabeled compounds, adhering to strict cGMP standards for sterile, radioactive drug preparation. Their technical expertise spans radiopharmaceutical synthesis, quality control, radiometric assay validation, and cold kit formulation, with demonstrated proficiency in handling short-lived isotopes and ensuring timely, just-in-time delivery to clinical sites. A key differentiator is their focused capability in nuclear pharmacy logistics, enabling reliable supply chains for PET and SPECT imaging agents used in oncology, cardiology, and neurology. The contractor maintains a consistent and deep relationship with the Department of Veterans Affairs, supplying radiopharmaceuticals to VA medical centers nationwide for diagnostic imaging and targeted radionuclide therapy. They also support the Department of Defense, providing radiopharmaceuticals under blanket purchase agreements to military treatment facilities, particularly in Florida, indicating a trusted role in defense healthcare operations. Their work is centered on mission-critical nuclear medicine services that support patient care in veteran and military populations. Primarily operating under NAICS 325412, the company is a specialized manufacturer of pharmaceutical preparations involving radioactive materials, distinguishing itself in the niche radiopharmaceuticals segment rather than general drug production. Their market positioning is that of a high-reliability supplier to government healthcare systems requiring regulated, on-demand radiopharmaceutical delivery. As a 2L entity headquartered in Orlando, Florida, Jubilant DraxImage operates without federal certifications but maintains rigorous compliance with FDA and NRC regulations governing radioactive drug manufacturing. Their geographic presence supports national distribution networks critical to federal medical supply chains, with operations calibrated to meet the unique demands of government nuclear medicine programs.